Culié D, Schiappa R, Modesto A, et al. - Researchers here examined how the initial therapeutic strategy affects the oncologic outcomes in patients with HPV-positive OPSCC. They retrospectively included 382 patients with p16-positive OPSCCs and classified them according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs non-surgical strategy (definitive radiotherapy ± chemotherapy). Outcomes revealed higher recurrence-free survival among p16+ OPSCC patients in correlation with undergoing upfront surgery vs definitive radiotherapy ± chemotherapy, however, there appeared no impact of management strategy on overall survival.